Why did the disrupter-in-chief settle for fine-tuning the drug market that everybody (other than pharma CEOs) hates?
from Forbes Real Time https://www.forbes.com/sites/stanfleming/2018/05/24/good-news-for-patients-trump-wont-dramatically-lower-drug-prices/
via IFTTT
No comments:
Post a Comment